leisure time -WSS

leisure time

author：explore 2025-10-02 12:31:58 - browse：96

Gene therapy helped Conner Curran, right, walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. -- Biotech coverage from STAT — Gene therapy helped Conner Curran (at right) walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. Courtesy Jess & Chris Curran

In the beginning, Conner Curran ran up the stairs.

It was a miraculous moment for him and his parents, Jess and Chris Curran. Just months before, contractors were in their New York home to install a motorized lift, while Jess tearfully explained that it wasn’t for a grandparent but for their 7-year-old son, who suffered from Duchenne muscular dystrophy and could barely haul himself up the steps.

Then Conner was accepted as the first patient in Pfizer’s Duchenne gene therapy trial. Three weeks later, he could bound to the second floor. Soon, he could walk the two-plus miles to Goldberg’s, a local bagel shop. “I couldn’t do that before,” he told NPR in 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Future doctors need a strong humanities education

WSS

Future doctors need a strong humanities education

Printout prescription drug information shouldn’t go digital

Violet CEO on training clinicians to promote more inclusive care

Inaction leaves children at risk from dangerous chemotherapy drug

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Grail spinoff by Illumina should end disastrous merger attempt

knowledge

leisure time

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

A pediatrician calls for Congress to pass the child tax credit deal

The high cost of giving birth even with insurance

Editas, Vertex strike deal on CRISPR

In age of alternative facts, a scholarly course on calling out crap

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Christmas in the PICU brings some surprising joy

New air purifier tech could be key to improving indoor air quality

High breast density mammograms need follow

hotspot

How to keep neuroscience’s past racism from being its future

Editas, Vertex strike deal on CRISPR

SEC charges former device maker CEO with $41 million fraud

What STAT readers think about the FDA and patient advocacy

David Ricks of Eli Lilly: best biopharma CEO of 2023

Readout Newsletter: The latest on Moderna, Apellis, and Merck

explore

focus

hotspot

hotspot